Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Myriad Genetics, Inc. (NASDAQ: MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Fintel reports that on May 21, 2025, Scotiabank downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Sector Outperform to Sector Perform. Analyst Price Forecast Suggests 244.58% ...

But moves this big are rare even for Myriad Genetics and indicate this news significantly impacted the market’s perception of the business.

About Myriad Genetics Myriad Genetics is a leading molecular diagnostics testing and precision medicine company dedicated to advancing health and well-being for all.

Quantbot Technologies LP grew its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 236.6% during the fourth quarter, HoldingsChannel reports. The institutional investor ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad reaffirms guidance and names a new CEO.

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ETCompany ParticipantsMatt Scalo - Senior Vice President of ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for recovery in the 'buy zone'.

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's ...